GlassScriptPhysician profile
Andrew Assaf
NPI 1508214321
$14,886.48
in general payments reported to CMS, 2019-2025
31 companies · $1,411 in 2025
The $1,411 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $1,148 · 2021: $1,441 · 2022: $3,090 · 2023: $4,747 · 2024: $1,940 · 2025: $1,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,296 · Travel and Lodging: $2,787 · Entertainment: $14.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,296.31 |
| Travel and Lodging | $2,787.19 |
| Entertainment | $14.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,514.84 | 2019-2025 | Perclose Prostyle, Optis, Esprit |
| Inari Medical, INC. | $986.04 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medtronic, INC. | $932.72 | 2021-2025 | Corevalve Evolut R, In.Pact Admiral, Hawkone |
| Shockwave Medical, INC | $658.64 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $597.87 | 2021-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $519.57 | 2019-2023 | Lifevest |
| Edwards Lifesciences Corporation | $479.37 | 2019-2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $447.35 | 2020-2025 | Eluvia |
| Abiomed | $431.50 | 2022-2024 | Impella |
| Penumbra, INC. | $327.34 | 2021-2025 | Indigo System |
| Janssen Pharmaceuticals, INC | $277.65 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $265.60 | 2019-2025 | |
| Heartflow, INC. | $263.93 | 2024-2025 | |
| Cardiovascular Systems INC. | $254.71 | 2020-2022 | |
| Medtronic Vascular, INC. | $237.94 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opsens INC. | $208.44 | 2022-2023 | Optowire |
| E.R. Squibb & Sons, L.L.C. | $188.88 | 2022-2023 | Camzyos |
| Philips North America LLC | $184.95 | 2020-2023 | |
| W. L. Gore & Associates, INC. | $182.39 | 2021-2024 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Stryker Corporation | $151.87 | 2025 | Venacore Thrombectomy Catheter, Artix Mt |
| Genzyme Corporation | $149.99 | 2022 | |
| Merck Sharp & Dohme LLC | $137.21 | 2022-2023 | Verquvo |
| Alnylam Pharmaceuticals INC. | $123.40 | 2025 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $119.31 | 2019 | |
| Chiesi USA, INC. | $95.61 | 2022 | |
| Pfizer INC. | $53.49 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.40 | 2019 | |
| Angiodynamics, INC. | $17.95 | 2024 | Auryon Laser System 100-120 Vac |
| Teleflex LLC | $17.07 | 2023 | Manta |
| Cordis US Corp. | $16.89 | 2023 | Zephyr |
| Truvic Medical, INC. | $16.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Assaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.